reports
InterCure Receives Nasdaq Notification Regarding Minimum Bid Requireme...
InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement NEW YORK and HERZLIYA, Israel, March 03, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (“InterCure” or the “Company”) today announced that on February 25, 2026 the Company received a written notice (the “Notice”) from the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(2), as the Company’s closing bid price for its ordinary shares, or Ordinary Shares, was below $1.00 per share for the last 30 consecutive business days. Pursuant to Nasda...
Guangdong Orient Zirconic Ind Sc&Te: 2 directors
Two Directors at Guangdong Orient Zirconic Ind Sc&Te sold 409,900 shares at between 15.480CNY and 15.750CNY. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company'...
Waste Management Inc: 4 directors
Four Directors at Waste Management Inc sold/sold after exercising options 22,111 shares at between 241.813USD and 243.128USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Graphic Packaging International, LLC and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 26 February 2026 in which we reassessed the appropriateness of the rat...
Lam Research Corp: 2 directors
Two Directors at Lam Research Corp sold after exercising options/sold 44,329 shares at between 230.220USD and 232.500USD. The significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all...
Nordrest Holding AB: 1 director
A director at Nordrest Holding AB sold 8,000 shares at 309.000SEK and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
ProQR Announces Webcast of Presentation at the 2026 Citizens Life Scie...
ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference LEIDEN, Netherlands & CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that company management will present at the Citizens Life Sciences Conference on Wednesday, March 11, 2026 at 3:25pm ET. A live webcast and recording of this presentation will be available from the “Investors & Me...
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Finan...
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026 DEER PARK, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Participant Call Lin...
Information Regarding the Total Number of Voting Rights and Total Numb...
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights02/28/2026 278,352,082 Total gross of voting rights: 278,352,082 Total net* of voting rights: 278,236,200 * Net total = total number of voting rights at...
Information relative au nombre total des droits de vote et d’actions c...
Information relative au nombre total des droits de vote et d’actions composant le capital social au 28 février 2026 Information relative au nombre total des droits de vote et d’actions composant le capital social au 28 février 2026 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE Euronext Paris Code ISIN : FR 0010417345 Date Nombre totald’actionscomposant le capital socialNombre totalde droits de vote28/02/2026 278.352.082 Total brut des droits de vote : 278.352.082 Total net* des droits de vote : 278.236.200 *Total net = nombre tot...
Castle Biosciences Announces Grand Opening of New Corporate Headquarte...
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will host a grand opening celebration for its new corporate headquarters on Tuesday, March 24, 2026, at 3:00 p.m. Central time. The event will take place at the Company’s new campus located at 1500 West Parkwood Avenue in Friendswood, Texas, and will bring together employees, community partners and oth...
Capital Power declares dividends for its Common and Preference shares
Capital Power declares dividends for its Common and Preference shares EDMONTON, Alberta, March 03, 2026 (GLOBE NEWSWIRE) -- The Board of Directors for Capital Power Corporation (“Capital Power”) (TSX: CPX) declared a dividend of $0.6910 per share on the outstanding common shares for the quarter ending March 31, 2026. The dividend is payable on April 30, 2026 to shareholders of record at the close of business on March 31, 2026. The Board of Directors also declared the following dividends on its Cumulative Rate Reset Preference Shares: SharesTSX Stock SymbolDividend Per ShareRecord DatePay...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 563...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, March 03, 2026 (GLOBE NEWSWIRE) -- (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 205,000 shares of the Company's common stock, effective as of March 2, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Direct...
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 America...
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting CHATHAM, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated, commercial biotechnology company, announced today that a poster on Tonmya™ (cyclobenzaprine HCl sublingual tablets), which was investigated as TNX-102 SL, will be presented at the 2026 American Academy of Pain Medicine (AAPM) PainConnect Annual Meeting, being held March 5–8, 2026, in Salt Lake City, Utah. A copy of the ...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Keysight Technologies, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 26 February 2026 in which we reassessed the appropriateness of the ratings in t...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Viatris Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 26 February 2026 in which we reassessed the appropriateness of the ratings in the context of t...
Kraken Robotics Announces Signing of Strategic Acquisition to Expand G...
Kraken Robotics Announces Signing of Strategic Acquisition to Expand Global Maritime Capabilities $615 Million Acquisition of the Covelya Group Will Be Partially Financed Through a $350 Million Public Offering of Subscription Receipts Preliminary 2025 Year-End Results and Stand-Alone 2026 Guidance Provided for Kraken Robotics THIS RELEASE IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES THE BASE SHELF PROSPECTUS IS ACCESSIBLE, AND THE SHELF PROSPECTUS SUPPLEMENT FOR THE PUBLIC OFFERING AND ANY AMENDMENT TO THE DOCUMENTS WILL BE ACCESSIB...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.